Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1995-06-06
2000-11-14
Peselev, Elli
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514 23, 514 62, 536 53, 536 552, A61K 3170
Patent
active
061470597
ABSTRACT:
Pharmaceutical compositions from which effective non-toxic (to the patient) dosage amounts may be taken and applied to the skin and/or exposed tissue of a human, each effective dosage amount comprising pharmaceutical excipients suitable for topical application, an effective non-toxic dosage amount of a drug to treat and to assist to resolve a disease and/or condition of the skin and/or exposed tissue or a human and an effective non-toxic dosage amount of hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments, and/or sub-units or hyaluronic acid sufficient to transport (to facilitate or cause the transport of) the drug, to a site in the skin including epidermis or exposed tissue or a disease or condition for percutaneous transport into the skin and/or exposed tissue to accumulate and remain there for a prolonged period of time and which is systemic independent acting.
REFERENCES:
patent: 2583096 (1952-01-01), Hididian et al.
patent: 3436454 (1969-04-01), Nouvel
patent: 3887703 (1975-06-01), Manoussos et al.
patent: 4141973 (1979-02-01), Balazs
patent: 4272522 (1981-06-01), Balazs
patent: 4303676 (1981-12-01), Balazs
patent: 4582865 (1986-04-01), Balazs et al.
patent: 4636524 (1987-01-01), Balazs et al.
patent: 4684627 (1987-08-01), LeVeen et al.
patent: 4711780 (1987-12-01), Fahim
patent: 4716224 (1987-12-01), Sakurai et al.
patent: 4725585 (1988-02-01), Wenge et al.
patent: 4736024 (1988-04-01), Della Valle et al.
patent: 4755544 (1988-07-01), Makino et al.
patent: 4795741 (1989-01-01), Leschiner et al.
patent: 4801619 (1989-01-01), Lindblad
patent: 4808576 (1989-02-01), Schultz et al.
patent: 4814176 (1989-03-01), Makino et al.
patent: 4840941 (1989-06-01), Ueno et al.
patent: 4851521 (1989-07-01), della Valle et al.
patent: 4853226 (1989-08-01), Machida et al.
patent: 4937254 (1990-06-01), Sheffield et al.
patent: 4946870 (1990-08-01), Partain, III et al.
patent: 4957744 (1990-09-01), della Valle et al.
patent: 4965353 (1990-10-01), della Valle et al.
patent: 4970298 (1990-11-01), Silver et al.
patent: 5095037 (1992-03-01), Iwamitsu et al.
patent: 5166331 (1992-11-01), della Valle et al.
Sandra Blakeslee, "Solid cores of tumors keeping out best drugs", Jul. 8, 1989 edition of the Globe and Mail, Toronto, Ontario, p. D4.
Pam Harrison, "Toxic drug tamed but still potent" Ontario Medicine, vol. 8, No. 16 dated Aug. 21, 1989, p. 1.
The Merck Index Eleventh Edition, Centennial Edition, Hyaluronic Acid formulation, pp. 751 and 752.
Alan R. Liss, Inc., Modulation of Immunity in Cancer Patients by Prostaglandin Antagonists, Immunity to Cancer II (will follow).
Goodwin, J.S. Prostaglandin E and Cancer Growth Potential for Immunotherapy with Prostaglandin Synthesis Inhibitors, Augmentive Agents in Cancer Therapy, Raven Press, New York, (1981) (will follow).
Dr. Samuel Asculai, "Inactivation of Herpes Simplex Viruses by Nonionic Surfactants", Antimicrobial Agents and Chemotherapy, Apr. 1978, pp. 686-690 (will follow).
Alaverdyan MI, Ter-Avetisyan AT. Effect of hyaluronidase, hyaluronic acid, and some other substances on postradiational experimental bacteriemai. Bulletin of Experimental Biology and Medicine 1967; 64(9): 967-969.
Balaza EA, Gibbs DA. The rheological properties and biological function of hyaluronic acid. In: Chemistry and Molecular Biology of the Intercellullar Matrix. Vol. III. New York: Academic Press, 1970. pp. 1241-1253.
Balazs EA, Band P. Hyaluronic acid: Its structure and use. Cosmetics & Toiletries. Polymers in Cosmetics 1984; 99: 65-72.
Camber O, Lundgren P. Diffusion of some low molecular weight compounds in sodium hyaluronate. Acta Pharmaceutica Suecica 1985; 22(6): 315-320.
Camber O, Edman P, Gurny R. Influence of sodium hyaluronate on the meiotic effect of pilocarpine in rabbits. Current Eye Research 1987; 6(6): 779-784.
Chang S-C. Pro-drug and vehicle approaches to improve the therapeutic index of topically applied timolol in the pigmented rabbit. Dissertation Abstracts International 1988; 49(2): 367-B.
Cravioto, R.O., et al. Effects of Precipitates Formed by Insulin with Hyaluronic Acid and Mucoid From Vitreous Humor in Depressing Blood-Sugar Levels Science (1950); vol. 111: 520-521.
Gieldanowski, Jerzy; Skowronska, Jadwiga Studies on immunosuppressive and anti-inflammatory effect of adriamycin. Arch. Immunol. Ther. Exp. (1980); 28 (3):439-446.
Hassan HG, Akerman B, Ranck H, Lindberg B, Lindquist B. Effects of adjuvants to local anaesthetics on their duration. Acta Anaesthesiol. Scand. 1985; 29: 384-388.
Hurd ER Immunosuppressive anti-inflammatory properties of cyclophosphamide, azathioprine and methotrexate. Arthritis and Rheumatism (Jan.-Feb. 1973); 16 (1): 84-88.
Idson B. Polymers in skin cosmetics. Cosmetics & Toiletries 1988; 103: 63-68.
Johansson A, Hassan H, Renck H. Effects of adjuvants to local anaesthetics on their duration. Acta Anaesthesiol. Scand. 1985; 29: 736-738.
Kalbhen D.A. The inhibitory effects of steroidal and non-steroidal antirheumatic drugs on articular cartilage in osteoarthrosis and its counteraction by a biological GAG-peptide complex (Rumalon.RTM.). Z. Rheumatol (1982); 41: 202-211.
Katsu M., Abe T., Shimada S. Significance and clinical use of non-steroid anti-inflammatory drugs as substitutes steroids in steroid dependence. Nippon Rinsho (Jan. 1968); 26(1): 89-95.
Kreis H, Chkoff N, Droz D, et al. Nonsteroid anti-inflammatory agents as a substitute treatment for steroids in ATGAM-treated cadaver kidney recipients. Transplantation (Feb. 1984); 37(2): 139-145.
McIlwraith W. Current concepts in equine degenerative joint disease. Journal of the American Veterinary Medicine Association 1982; Feb. 1: 239-250.
Mizushima, Y. Possibility of non-steroid anti-inflammatory drugs as a sustitute for steroids-analysis of the present situation and demands for the future. Nippon Rinsho (Jan. 1986); 26(1): 61-65.
Nizolek DJH, White KK. Corticosteroid and hyaluronic acid treatments in equine degenerative joint disease: A reveiw. The Cornell Veterinarian 1981; 71(4): 355-375.
Pigman W, et al. Acide hyaluronique et facteurs de permeabilite tissulaire. Bull. Soc. Chim. Biol. 1963: 5(2-3): 185-202.
Pruett RC, Schepens CL, Constable IJ, Swann DA. Hyaluronic Acid vitreous substitute. In: Vetreous Surgery and Advances in Fundus Diagnosis and Treatment. Freeman, H.M., et al., Editors. Appleton-Century-Crofts, 1977: Chapter 55. pp. 433-444.
Reim M, Teping C. Surgical procedures in the treatment of most severe eye burns. Acta Ophthalmologica 1989-Supplementum 192; 67: 47-54.
Rydell NW, Balazs EA. Effect intra-articular injection of hyaluronic acid on the clinical symptoms of osteoarthritis and on granulation tissue formation. Clinical Orthopaedics and Related Research 1971; 80(Oct.): 25-29.
Saba P, Galeone F, Salvadorini F. Guarguaglini M, Ombrato M. Investigation of the antihyperlipemic activity of an association of clofibrate and extractive mucopolysaccharide complex. Current Therapeutic Research 1978; 23(4): 455-463.
Stegman R, Miller D. Use of sodium hyaluronate in severe penetrating ocular trauma. Acta Ophthamol. 1986; 18: 9-13.
Trabucchi E, Foschi D, Marazzi M, Radaelli E, Lucianetti A, Rizzitelli E, Baratti C, et al. Prevention of wound dehiscence in severely obese patients with jejuno-ileal by-pass: The role of hyaluronic acid. Pharmatherapeutica 1988; 5(4): 233-239,
Sertoli P, Merello A, Parodi M. L'acido jaluronico, per uso topico, nella cura delle ulcere trofo-cricolatorie degli arti inferiori. (Comunicazioni). Giornale Italiano di Dermatologia 1970; 45(8): 468-471.
Walther, M. The Prevetion of Strine Cutis Distansae During Pregnancy. Mineva Gynecolgia (1981) vol. 33: 497-499.
Weirich, E.G., Longauer, J.K,. Kirkwood, A.H. Dermatopharmacology of salicylic acid. III. Topical contra-inflammatory effect of salicylic acid and other durgs in animal experiments. Dermatologica (1976); 152(2): 87-99.
Blakeslee, S., "Solid cores of tumors keeping out best drugs", Jul. 8, 1989 edition of The Glove and Mail, Toronto, Ont., p. D4.
Harrison, P., "Toxic drug tamed but still potent", Ontario Medicine, vol. 8,
Asculai Samuel S
Falk Rudolf E
Harper David W
Hochman David
Klein Ehud S
Hughes Ivor M.
Hughes Neil H.
Hyal Pharmaceutical Corporation
Peselev Elli
Sarkis Marcel K.
LandOfFree
Formulations containing hyaluronic acid does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Formulations containing hyaluronic acid, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Formulations containing hyaluronic acid will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2065543